Free Trial

Arcus Biosciences (RCUS) Competitors

Arcus Biosciences logo
$16.64 +2.04 (+13.95%)
Closing price 10/13/2025 03:59 PM Eastern
Extended Trading
$16.84 +0.20 (+1.22%)
As of 10/13/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RCUS vs. PCVX, MTSR, KRYS, PTCT, ARWR, ACLX, KYMR, PTGX, CRNX, and ZLAB

Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.

Arcus Biosciences vs. Its Competitors

Arcus Biosciences (NYSE:RCUS) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arcus Biosciences has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$258M6.86-$283M-$3.17-5.25
VaxcyteN/AN/A-$463.93M-$4.11-10.66

Vaxcyte has a net margin of 0.00% compared to Arcus Biosciences' net margin of -109.56%. Vaxcyte's return on equity of -16.85% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcus Biosciences-109.56% -55.96% -25.73%
Vaxcyte N/A -16.85%-15.92%

In the previous week, Arcus Biosciences had 11 more articles in the media than Vaxcyte. MarketBeat recorded 18 mentions for Arcus Biosciences and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.99 beat Arcus Biosciences' score of 0.20 indicating that Vaxcyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcus Biosciences
5 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Vaxcyte
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Arcus Biosciences currently has a consensus price target of $26.78, indicating a potential upside of 60.95%. Vaxcyte has a consensus price target of $106.25, indicating a potential upside of 142.52%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Arcus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Arcus Biosciences has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Summary

Vaxcyte beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCUS vs. The Competition

MetricArcus BiosciencesMED IndustryMedical SectorNYSE Exchange
Market Cap$1.55B$3.36B$6.05B$21.48B
Dividend YieldN/A2.31%5.73%3.67%
P/E Ratio-5.2522.0885.3129.66
Price / Sales6.86478.69601.4686.18
Price / CashN/A44.9825.7717.79
Price / Book3.1410.3812.674.63
Net Income-$283M-$52.47M$3.32B$1.01B
7 Day Performance18.71%0.18%-0.05%-0.80%
1 Month Performance44.67%13.95%8.73%0.55%
1 Year Performance-7.78%20.83%78.85%13.03%

Arcus Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCUS
Arcus Biosciences
1.9677 of 5 stars
$16.64
+14.0%
$26.78
+61.0%
-9.4%$1.55B$258M-5.25500News Coverage
Analyst Forecast
Gap Up
PCVX
Vaxcyte
2.3013 of 5 stars
$41.21
-3.4%
$106.25
+157.8%
-61.7%$5.54BN/A-10.03160
MTSR
Metsera
N/A$52.50
+1.2%
$55.75
+6.2%
N/A$5.45BN/A0.0081
KRYS
Krystal Biotech
4.4962 of 5 stars
$180.57
-1.5%
$209.00
+15.7%
+3.4%$5.31B$359.21M36.70210Analyst Revision
PTCT
PTC Therapeutics
3.2633 of 5 stars
$64.80
-0.9%
$69.00
+6.5%
+69.4%$5.19B$1.76B9.301,410Analyst Revision
ARWR
Arrowhead Pharmaceuticals
4.0189 of 5 stars
$37.50
+3.8%
$43.14
+15.0%
+96.6%$4.99B$3.55M-29.30400
ACLX
Arcellx
2.0189 of 5 stars
$84.38
-0.8%
$114.31
+35.5%
+0.0%$4.72B$107.94M-24.6780Analyst Revision
KYMR
Kymera Therapeutics
1.3652 of 5 stars
$57.55
-0.6%
$61.26
+6.5%
+33.0%$4.14B$47.07M-16.58170
PTGX
Protagonist Therapeutics
1.6737 of 5 stars
$64.14
-1.1%
$68.36
+6.6%
+75.6%$4.03B$434.43M91.63120Analyst Forecast
CRNX
Crinetics Pharmaceuticals
3.7167 of 5 stars
$41.68
+2.0%
$74.45
+78.6%
-16.4%$3.85B$1.04M-10.14210
ZLAB
Zai Lab
2.5957 of 5 stars
$33.31
-1.3%
$56.35
+69.2%
+23.3%$3.77B$398.99M-16.331,869News Coverage
Positive News

Related Companies and Tools


This page (NYSE:RCUS) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners